top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Quentin McCubbin net worth and biography

Quentin McCubbin Biography and Net Worth

Insider of Frequency Therapeutics

Quentin McCubbin, PhD, joined Frequency Therapeutics in January 2021 as Chief Manufacturing Officer. In this role, he oversees technical operations, leading overall efforts in drug product formulation, chemistry manufacturing and controls (CMC) and supply chain to support the development of Frequency’s pipeline of product candidates.

Dr. McCubbin joined Frequency from Cerevel Therapeutics, a clinical-stage biotechnology company where he served as Head of Technical Operations for two years. Prior to Cerevel, he spent 19 years at Takeda/Millennium Pharmaceuticals in variety of roles including six years as Vice President of Pharmaceutical Sciences and Global Head of Process Chemistry. He began his career as a chemist, completing a post-doctoral fellowship at Imperial College in London. He earned his B.S. and Ph.D. in Chemistry from Monash University in Australia. He is an inventor on several patents and has published numerous peer-reviewed articles.

How do I contact Quentin McCubbin?: The corporate mailing address for Dr. McCubbin and other Frequency Therapeutics executives is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. Frequency Therapeutics can also be reached via phone at 781-315-4600 and via email at [email protected]. Learn More on Quentin McCubbin's contact information.
Has Quentin McCubbin been buying or selling shares of Frequency Therapeutics?: Quentin McCubbin has not been actively trading shares of Frequency Therapeutics during the past quarter. Learn More on Quentin McCubbin's trading history.
Who are Frequency Therapeutics' active insiders?: Frequency Therapeutics' insider roster includes Carl LeBel (Insider), Christopher Loose (Insider), Quentin McCubbin (Insider), and Peter Pfreundschuh (CFO). Learn More on Frequency Therapeutics' active insiders.
Are insiders buying or selling shares of Frequency Therapeutics?: During the last twelve months, insiders at the sold shares 46 times. They sold a total of 65,319 shares worth more than $36,102.94. The most recent insider tranaction occured on August, 18th when VP Richard J Mitrano sold 227 shares worth more than $143.01. Insiders at Frequency Therapeutics own 16.8% of the company. Learn More about insider trades at Frequency Therapeutics.
Information on this page was last updated on 8/18/2023.

Quentin McCubbin Insider Trading History at Frequency Therapeutics

Quentin McCubbin Buying and Selling Activity at Frequency Therapeutics

Frequency Therapeutics Company Overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $0.30

$0.28

$0.32

50 Day Range

MA: $0.58

$0.22

$14.98

2 Week Range

Now: $0.30

$0.18

$16.00

Volume

309,164 shs

Average Volume

822,537 shs

Market Capitalization

$10.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84